Migraine, a prevalent and debilitating neurological condition, significantly impairs quality of life and functional capacity. Current pharmacological treatments side effect profile underscore the need for novel therapeutic interventions that are both effective and better tolerated.

Cannabis (Vijaya extract) has been proposed as a potential therapeutic agent for migraine due to its analgesic, anti-inflammatory, and anti-emetic properties. Both oral and topical formulations of cannabis may offer a novel approach to managing migraine symptoms. The rationale for this study is based on the hypothesis that cannabis can effectively reduce migraine frequency, severity, and associated disability without the adverse effects commonly seen with conventional treatments.

This study aims to provide scientific evidence on the efficacy and safety of cannabis (Vijaya extract) in treating migraine without aura. By comparing the impact of oral, topical, combined and placebo formulations this research seeks to identify optimal therapeutic strategies that offer rapid and consistent relief, restore patient functionality, and minimize adverse effects. The outcomes could lead to the development of new, effective, and well-tolerated treatments for migraine, improving the quality of life for patients and reducing the burden on healthcare systems and burden of disease overall due to improved ability to work / increased workplace productivity.